Health Canada proposes to increase fees to the pharmaceutical industry for prescription drug approval. This will compromise drug safety and is a risk to the health of the Canadian public.
Academic rigour, journalistic flair
Articles on Food and Drug Administration (FDA)
Displaying 121 - 140 of 160 articles
Philip Morris has applied to the FDA to market a product that it says is safer than a cigarette, but its own data show that is not true.
The herb kratom has a large following and is so popular that it is sold in vending machines. The FDA recently issued a public warning about the herb, which contains low levels of opioids.
A successful gene therapy for the leading cause of sight loss in children is being reviewed by the FDA.
How can we fight the opioid epidemic? Redesign the drugs, rethink how we assess patients and mandate prescription monitoring.
Pacemakers are Internet of Things devices for the human body, but they’re still not particularly secure.
Companies are exploiting a knowledge gap with consumers and fears of the supposed health hazards of certain ingredients with so-called absence labels.
FDA Director Scott Gottlieb has proposed discussions about drastically cutting nicotine levels in cigarettes. This could result in some of the biggest health gains in history.
Regulatory bodies approved some medical devices to treat pelvic organ prolapse and urinary incontinence before having data to prove their safety and efficacy.
In planes, trains and cars, we increasingly entrust our lives to automated safety systems. It’s time for medical technology to catch up.
Reports about trace amounts of pesticides, like the EWG’s Dirty Dozen, can leave people afraid to buy fruits and vegetables. But the hype is often overblown.
Intuitively, it might seem desirable to speed up access to medicines. But this means more drugs will be approved that may subsequently prove unsafe or ineffective.
Dogs are great companions, and they also are proving to be great research subjects for cancer. Here’s how our canine friends are pointing to possible treatments in human cancer.
Products not under the FDA’s jurisdiction don’t have to list whether they contain any of the antimicrobial chemicals banned in soap by the agency.
Lowering the threshold for FDA approval and feeding the agency less rigorous information will increase the likelihood of approvals of unsafe or ineffective drugs and devices.
By getting young women hooked before they’ve even formed wrinkles, Botox peddlers have realized they can enlist them in a lifetime of treatment.
There is conflicting medical evidence.
The maker of the EpiPen has raised the price of two injectable treatments to about US$600, six times the price nine years ago. Why do drug companies do this? Because they can. The FDA ends up helping.
The FDA recently advised people not to eat raw cookie dough because raw flour with E. coli in it had sickened 38 people. Do we really have to forgo our favorites?
Federal officials could give the FDA authority to develop e-cigarette regulations. But developing regulations that maximize their benefits and minimize their risks is harder than it looks.
Job Board
-
Associate Professor, Occupational Therapy
-
GRAINS RESEARCH AND DEVELOPMENT CORPORATION CHAIRPERSON
-
Technical Skills Laboratory Officer
-
Faculty of Law - Academic Appointment Opportunities
-
Audience Development Coordinator (fixed-term maternity cover)
Top contributors
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Professor of Law, Villanova School of Law
-
Associate Professor of Public Policy, University of Maryland, Baltimore County
-
Associate Professor of Pharmacy and Therapeutics, University of Pittsburgh
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor of Molecular Medicine, UMass Chan Medical School
-
Professor and Dean, School of Public Health, Georgia State University
-
Instructor of Human Immunology, Emory University
-
Associate Professor of Pediatrics, University of Virginia
-
Clinical Associate Professor of Pharmacy Practice, Binghamton University, State University of New York
-
Associate Professor of Operations and Decision Technologies, Kelley School of Business, Indiana University
-
Professor of Law, George Washington University
-
Doctorate in Health Sciences candidate, George Washington University
-
Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco
-
Associate Professor of Legal Studies and Political Science, UMass Amherst
